SAN DIEGO, Oct. 15, 2019 /PRNewswire/ — Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced FDA’s approval to initiate Denovo’s Phase 2b clinical study of DB102 in patients with newly-diag… […]
SAN DIEGO, Oct. 15, 2019 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases, today announced that the Company will present at… […]
SAN DIEGO, Oct. 15, 2019 /PRNewswire/ — Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, president and chief executive officer, will present a… […]
SAN DIEGO, Oct. 15, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced … […]
SAN DIEGO, Oct. 14, 2019 /PRNewswire/ — Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a compan… […]
Conference Call and Webcast Scheduled for Monday, November 4
SAN DIEGO, Oct. 14, 2019 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Mo… […]
SAN DIEGO, Oct. 14, 2019 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD) (“Aethlon” or the “Company”), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that at the annual meeting of st… […]
– Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 –
SAN DIEGO, Oct. 10, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, ora… […]
SAN DIEGO, Oct. 10, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced that Mr. Saiid Zarrabian, Chief Executive Off… […]
SAN DIEGO and COPENHAGEN, Denmark, Oct. 9, 2019 /PRNewswire/ — AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced results from a Phase 1 clinical proof of concep… […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
